VNDA

Vanda is a two-sided story the numbers make vivid. On one side, the P&L deteriorated sharply in FY2025: net income swung to -$220M from -$18.9M a year earlier (-1066%), operating income fell to -$151M (net margin -102%, operating margin -70%), and operating cash flow turned to -$109M against a $84.9M cash balance. The MD&A explains the pressure — HETLIOZ is being eroded by at-risk generic launches from Teva, Apotex and MSN following the lost patent litigation, while the company simultaneously ramped R&D 47% to $109M and funded a new direct-to-consumer campaign. The result is a business spending aggressively into a franchise transition, and the -$395M accumulated deficit reflects how much value that has consumed.

On the other side, the balance sheet is not distressed and the growth engine is real. Liabilities/equity is only 0.49x, current assets of $347M cover current liabilities of $145M ~2.4x, and equity is still $327M — the ~$200M of net working capital implies liquid investments well beyond the headline cash line, giving multiple years of runway at the current burn. Crucially, Fanapt — the product management explicitly calls the commercial focus — grew net sales 24% for full-year 2025 with new-to-brand prescriptions up 149%, and total revenue still rose 8.7% to $216M despite the HETLIOZ generic hit. That is a genuine mix shift from a declining legacy asset toward a growing one.